3/11
09:00 am
capr
Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19
Low
Report
Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19
3/10
09:30 am
capr
FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment [Yahoo! Finance]
Low
Report
FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment [Yahoo! Finance]
3/10
09:13 am
capr
FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment
Medium
Report
FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment
3/7
10:42 am
capr
Capricor Therapeutics to Present at Leerink's Global Healthcare Conference 2025 [Yahoo! Finance]
Medium
Report
Capricor Therapeutics to Present at Leerink's Global Healthcare Conference 2025 [Yahoo! Finance]
3/7
09:25 am
capr
Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025
Medium
Report
Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025
3/4
12:28 pm
capr
Capricor Therapeutics Inc (NASDAQ: CAPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $77.00 price target on the stock.
Medium
Report
Capricor Therapeutics Inc (NASDAQ: CAPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $77.00 price target on the stock.
3/4
08:05 am
capr
Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy [Yahoo! Finance]
Medium
Report
Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy [Yahoo! Finance]
3/4
07:00 am
capr
Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy
Medium
Report
Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy
2/10
09:00 am
capr
Capricor Therapeutics to Participate in Upcoming Investor Conferences
Low
Report
Capricor Therapeutics to Participate in Upcoming Investor Conferences
1/2
11:18 am
capr
Capricor Therapeutics Inc (NASDAQ: CAPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $77.00 price target on the stock.
Medium
Report
Capricor Therapeutics Inc (NASDAQ: CAPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $77.00 price target on the stock.
1/2
09:15 am
capr
Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Medium
Report
Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy